Rani Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results
Rani Therapeutics (Nasdaq: RANI) will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026 after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Rani Therapeutics (Nasdaq: RANI) will report fourth quarter and full year 2025 financial results and provide a business update on Thursday, March 26, 2026 after market close. Management will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT.
Investors can access the live webcast and a replay via the company’s investor relations website at www.ranitherapeutics.com.
Details
News Market Reaction – RANI
On Mar 20, the first trading day after this news, RANI closed 1.74% below the previous close.
Data tracked by StockTitan Argus for the Mar 20 session.
Key Figures
- Earnings release date
- March 26, 2026
- Scheduled Q4 and full-year 2025 results release
- Period end date
- December 31, 2025
- Fourth quarter and full-year 2025 reporting period
- Conference call time ET
- 4:30 p.m. ET
- Start time for earnings call and webcast
- Conference call time PT
- 1:30 p.m. PT
- Pacific Time for earnings call and webcast
Historical Context
-
Promotion of Alireza Javadi, Ph.D., to Chief Technical Officer.
-
Initiation of Phase 1 study of RT-114 RaniPill for obesity.
-
Announcement of participation in the Evercore Healthcare Conference.
-
Q3 2025 financial results and Chugai collaboration plus financing update.
-
Preclinical data on oral semaglutide via RaniPill at ObesityWeek 2025.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
biologics medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN JOSE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2025 and provide a business update on Thursday, March 26, 2026 after the close of trading. Rani’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.
Conference Call and Webcast
Rani Therapeutics will host a conference call and live webcast at 4:30 p.m. ET / 1:30 p.m. PT on March 26, 2026. Individuals interested in listening to the live conference call may do so by using the webcast link in the “Investors” section of the company’s website at www.ranitherapeutics.com. A webcast replay will be available in the investor relations section on the company’s website following the completion of the call.
About Rani Therapeutics
Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill® capsule, which is a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill® capsule technology.
Investor Contact:
investors@ranitherapeutics.com
Media Contact:
media@ranitherapeutics.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.